Autonomix Medical, Inc. Selected for Podium Presentation at the 2025 CRT Annual Meeting
Autonomix Medical (NASDAQ: AMIX) has been selected to present its catheter-based technology and initial findings from its ongoing human clinical trial in pancreatic cancer pain patients at the 2025 Cardiovascular Research Technologies (CRT) Annual Meeting. The presentation, titled 'Catheter-Based Transvascular RF Neural Ablation For Severe Pancreatic Cancer Pain: First Results From The Elpis Study,' will be delivered by Dr. Robert Schwartz, Chief Medical Officer, on March 10, 2025.
The presentation will be featured in the Innovation HUB session, which showcases innovative products and services that haven't yet been fully market-released, including early-stage/prototype, pre-clinical, first-in-human, and CE Mark technologies. The CRT Annual Meeting, scheduled for March 8-11, 2025, in Washington, DC, is a prominent educational forum focusing on new cardiovascular technology and procedures.
Autonomix Medical (NASDAQ: AMIX) è stata selezionata per presentare la sua tecnologia basata su catetere e i risultati iniziali del suo studio clinico umano in corso sui pazienti con dolore da cancro pancreatico durante l'Annual Meeting 2025 delle Cardiovascular Research Technologies (CRT). La presentazione, intitolata 'Ablazione Neurale RF Transvascolare Basata su Catetere per il Dolore Grave da Cancro Pancreatico: Primi Risultati dallo Studio Elpis,' sarà tenuta dal Dr. Robert Schwartz, Chief Medical Officer, il 10 marzo 2025.
La presentazione sarà presente nella sessione Innovation HUB, che mette in evidenza prodotti e servizi innovativi che non sono ancora stati completamente lanciati sul mercato, inclusi tecnologie in fase iniziale/prototipi, pre-clinici, primi in umani e tecnologie con marcatura CE. L'Annual Meeting CRT, programmato per l'8-11 marzo 2025 a Washington, DC, è un forum educativo di rilievo che si concentra su nuove tecnologie e procedure cardiovascolari.
Autonomix Medical (NASDAQ: AMIX) ha sido seleccionada para presentar su tecnología basada en catéter y los hallazgos iniciales de su ensayo clínico humano en curso en pacientes con dolor por cáncer de páncreas en la Reunión Anual 2025 de Cardiovascular Research Technologies (CRT). La presentación, titulada 'Ablación Neural RF Transvascular Basada en Catéter para el Dolor Severo por Cáncer de Páncreas: Primeros Resultados del Estudio Elpis,' será realizada por el Dr. Robert Schwartz, Director Médico, el 10 de marzo de 2025.
La presentación se incluirá en la sesión Innovation HUB, que destaca productos y servicios innovadores que aún no han sido completamente lanzados al mercado, incluidos tecnologías en etapa temprana/prototipos, preclínicos, primeros en humanos y tecnologías con marcado CE. La Reunión Anual CRT, programada para el 8-11 de marzo de 2025 en Washington, DC, es un destacado foro educativo que se centra en nuevas tecnologías y procedimientos cardiovasculares.
Autonomix Medical (NASDAQ: AMIX)는 췌장암 통증 환자를 대상으로 진행 중인 인간 임상 시험의 카테터 기반 기술과 초기 결과를 2025년 심혈관 연구 기술(CRT) 연례 회의에서 발표하도록 선정되었습니다. '심각한 췌장암 통증을 위한 카테터 기반 경유 RF 신경 절제술: Elpis 연구의 첫 결과'라는 제목의 발표는 Dr. Robert Schwartz 최고 의료 책임자가 2025년 3월 10일에 진행할 예정입니다.
이 발표는 아직 완전히 시장에 출시되지 않은 혁신적인 제품과 서비스를 선보이는 Innovation HUB 세션에서 진행될 예정이며, 초기 단계/프로토타입, 전임상, 인간 최초, CE 마크 기술을 포함합니다. 2025년 3월 8일부터 11일까지 워싱턴 D.C.에서 예정된 CRT 연례 회의는 새로운 심혈관 기술과 절차에 중점을 둔 주요 교육 포럼입니다.
Autonomix Medical (NASDAQ: AMIX) a été sélectionnée pour présenter sa technologie basée sur un cathéter et les résultats préliminaires de son essai clinique humain en cours sur des patients souffrant de douleur liée au cancer du pancréas lors de la réunion annuelle 2025 des Cardiovascular Research Technologies (CRT). La présentation, intitulée 'Ablation Neurale RF Transvasculaire Basée sur Cathéter pour la Douleur Grave due au Cancer du Pancréas : Premiers Résultats de l'Étude Elpis,' sera effectuée par Dr. Robert Schwartz, Directeur Médical, le 10 mars 2025.
Cette présentation sera présentée lors de la session Innovation HUB, qui met en avant des produits et services innovants qui n'ont pas encore été entièrement lancés sur le marché, y compris des technologies en phase précoce/prototype, précliniques, premières sur l'homme et des technologies avec marquage CE. La réunion annuelle CRT, prévue du 8 au 11 mars 2025 à Washington, DC, est un forum éducatif de premier plan axé sur les nouvelles technologies et procédures cardiovasculaires.
Autonomix Medical (NASDAQ: AMIX) wurde ausgewählt, um ihre katheterbasierte Technologie und erste Ergebnisse aus ihrer laufenden klinischen Studie bei Patienten mit Pankreaskrebs-Schmerzen auf dem 2025 Cardiovascular Research Technologies (CRT) Jahrestreffen zu präsentieren. Die Präsentation mit dem Titel 'Katheterbasierte transvasale RF-Neuralablation bei schweren Pankreaskrebs-Schmerzen: Erste Ergebnisse aus der Elpis-Studie' wird am 10. März 2025 von Dr. Robert Schwartz, Chief Medical Officer, gehalten.
Die Präsentation wird in der Innovation HUB-Sitzung vorgestellt, die innovative Produkte und Dienstleistungen zeigt, die noch nicht vollständig auf dem Markt sind, einschließlich Technologien in der frühen Phase/Prototyp, präklinisch, erstmals am Menschen und CE-gekennzeichnete Technologien. Das CRT Jahrestreffen, das vom 8. bis 11. März 2025 in Washington, DC, stattfindet, ist ein bedeutendes Bildungsforum, das sich auf neue kardiovaskuläre Technologien und Verfahren konzentriert.
- None.
- None.
Presentation to highlight Autonomix’s catheter-based technology and key findings from lead-in patients in ongoing human clinical trial in pancreatic cancer pain patients
THE WOODLANDS, TX, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced it will present its technology and lead-in subject findings in a podium presentation at the 2025 Cardiovascular Research Technologies (CRT) Annual Meeting being held March 8-11, 2025 in Washington, DC.
The podium presentation will be part of the Innovation HUB session which features companies with innovative products/services that have not yet been fully market-released and with technology status that may include early stage/prototype, pre-clinical, first-in-human and CE Mark.
Details of the presentation are as follows:
Title: Catheter-Based Transvascular RF Neural Ablation For Severe Pancreatic Cancer Pain: First Results From The Elpis Study
Presenter: Dr. Robert Schwartz, Chief Medical Officer of Autonomix
Session Date and Time: Monday, March 10, 2025 from 2:00 PM – 2:40 PM ET
CRT is a leading educational forum on new cardiovascular technology and procedures for physicians and health-care professionals. CRT provides a forum for exemplary education for interventional cardiologists, general cardiologists, cardiothoracic and vascular surgeons, catheterization laboratory managers, nurses and technologists, scientists and those with an interest in cardiovascular medicine. The annual CRT meeting features focused educational and training sessions that discuss new trial data, explore evidence-based research and demonstrate the most up-to-date techniques that can be directly applied to clinical and academic practices
For more information about the CRT25, please visit the event website here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential of the technology to treat cancerous tumors and the pain associated with pancreatic cancer. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2024 and the Offering Prospectus filed with the SEC on November 25, 2024, and in other filings made by us from time to time with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
FAQ
When will Autonomix Medical (AMIX) present its pancreatic cancer pain treatment findings at CRT 2025?
What clinical trial results will AMIX present at the 2025 CRT Meeting?
What type of technology is Autonomix Medical (AMIX) developing for pancreatic cancer pain?
Which session will feature Autonomix Medical's (AMIX) presentation at CRT 2025?
